+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Complete metabolic remission with Gefitinib in a hemodialysis patient with bone metastases from non-small cell lung cancer



Complete metabolic remission with Gefitinib in a hemodialysis patient with bone metastases from non-small cell lung cancer



Anticancer Research 34(1): 319-322



Gefitinib is highly active in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growth factor receptor (EGFR) gene. The feasibility and the degree of response to treatment with gefitinib in patients with chronic renal failure (CRF) undergoing hemodialysis has not yet been fully described in literature. We describe the case of a 70-year-old man with CRF undergoing hemodialysis three times-a-week who developed vertebral and rib bone metastasis three years after lobectomy. The bone biopsy confirmed the pulmonary origin and pyrosequencing analysis revealed deletion in E746-E750 of exon 19. We started daily administration of 250 mg gefitinib with no changes in the hemodialysis schedule. Gefitinib was well-tolerated without any adverse event. After three months, the (18)F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (FDG PET/CT) showed complete metabolic remission of bone lesions. The patient is still under treatment and maintains response (30 months to date). To our knowledge, this is the first description of complete metabolic remission in this type of patient. In conclusion, gefitinib has been safely administered to a patient with NSCLC with EGFR-activating mutation undergoing chronic hemodialysis and its use has achieved an excellent and prolonged response on bone metastases.

(PDF emailed within 1 workday: $29.90)

Accession: 052259081

Download citation: RISBibTeXText

PMID: 24403481


Related references

Complete remission of multiple brain metastases of non-small cell lung cancer induced by gefitinib monotherapy. Strahlentherapie und Onkologie 187(12): 826-830, 2012

Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib. Lung Cancer 60(3): 452-454, 2007

Pharmacokinetic analysis of gefitinib in a patient with advanced non-small cell lung cancer undergoing hemodialysis. Thoracic Cancer 7(2): 251-253, 2016

Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis. Anticancer Research 34(6): 3185-3188, 2014

Cranial irradiation for preventing brain metastases of small cell lung cancer in patients in complete remission. Cochrane Database of Systematic Reviews: Cd002805-Cd002805, 2000

Brain metastases in patients with limited small cell lung cancer achieving complete remission. Correlation with TNM staging. Chest 96(6): 1332-1335, 1989

A case of complete response treated by S-1 with concurrent radiotherapy for a gefitinib-resistant non-small cell lung cancer patient. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 37(2): 295-298, 2010

Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib. American Journal of the Medical Sciences 333(4): 221-225, 2007

Acute myeloblastic leukemia development in a patient with small cell lung cancer in complete remission. Nihon Kyobu Shikkan Gakkai Zasshi 27(12): 1528-1533, 1989

Complete remission of renal cell carcinoma with lung metastases in two hemodialysis patients after low-dose interferon therapy. Hemodialysis International. International Symposium on Home Hemodialysis 15(2): 288-292, 2011

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. Journal of Clinical Oncology 24(27): 4517-4520, 2006

Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer. Blood 110(3): 1079-1080, 2007

Complete Remission of Brain Metastases in Non-Small Cell Lung Cancer Patients Harboring an EGFR Mutation Treated with Tyrosine Kinase Inhibitor without Radiotherapy: A Report of 3 Cases. Case Reports in Oncology 7(1): 149-154, 2014

Prevalence of brain metastases immediately before prophylactic cranial irradiation in limited disease small cell lung cancer patients with complete remission to chemoradiotherapy: a single institution experience. Journal of Thoracic Oncology 3(6): 652-655, 2008

Effect of gefitinib on brain metastases from non-small cell lung cancer. Neurologia Medico-Chirurgica 46(10): 504-507, 2006